Graduated with honors in Biology, Health and Biotechnology, with specialization in pathophysiology at the Institute of Cardiovascular and Metabolic Diseases (Toulouse, France). My research projects dealt with different aspects of heart failure and lung diseases to identify new therapeutic targets and strategies. During my early research career, I identified new Epac inhibitors and provided new alternatives for treating patients with heart failure or cancer. I also investigated for the first time the role of Carabin in cardiac hypertrophy and heart failure and identify a new potent therapeutic target. At the Institute of Cardiology and Pneumology of Quebec (Canada), I investigated the role of the receptor RAGE in pulmonary hypertension and its signaling pathway implicated in the vascular remodeling. At the Department of Pathology at Yale University (Connecticut, United States), my expertise in cell signaling and molecular pharmacology allowed me to investigate the role of pro-survival pathways and acquired-mutations of the EZH2 gene in conferring resistance to the EZH2 inhibitors-targeted therapies in Lymphoma. More recently, I accepted a new position in the Department of Cardiology at the Cardiovascular Research Center, at Mount Sinai (NewYork, United States) and initiated my studies on the identification and characterization of innovative therapeutic targets in lung diseases.
Malik Bisserier, PhD
Department of Cardiology
Cardiovascular Research Center
Icahn School of Medicine at Mount Sinai
One Gustave L. Levy Place, Box 1030
New York, NY 10029
T: (212) 824-9015